Semiconductor: $Semiconductor Manufacturing International Corporation (688981.SH)$ $NAURA Technology Group (002371.SZ)$
Securities: $CITIC (600030.SH)$ $East Money Information (300059.SZ)$
Insurance: $China Life Insurance (601628.SH)$   $Ping An Insurance (601318.SH)$
Auto Parts: $Fuyao Glass Industry Group (600660.SH)$ $Weichai Power (000338.SZ)$ $Ningbo Tuopu Group (601689.SH)$
Cars: $BYD Company Limited (002594.SZ)$
Software: $Beijing Kingsoft Office Software, Inc (688111.SH)$ $Hithink RoyalFlush Information Network (300033.SZ)$ $Iflytek Co.,ltd. (002230.SZ)$
...

In Q2, $WUXI APPTEC (02359.HK)$ ’s revenue was 9.261 billion yuan, up 16% quarter-over-quarter but down 6.5% year-over-year.
Adjusted non-IFRS net profit for Q2 was 2.46 billion yuan, up 28.5% quarter-over-quarter but down 10.6% year-over-year.
Revenue from U.S. clients was 10.71 billion yuan, down 1.2% year-over-year excluding specific commercial...

$Tasly Pharmaceutical Group (600535.SH)$  this is something we can consider accumulating

InnoCare Pharma ( $INNOCARE (09969.HK)$； $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first patient has been dosed in a clinical trial of the Company's BCL2 inhibitor, ICP-248, in combination with orelabrutinib as a first-line therap...

InnoCare Pharma ( $INNOCARE (09969.HK)$； $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.
This is a multicente...

InnoCare Pharma ( $INNOCARE (09969.HK)$； $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the release of its 2023 Environmental, Social, and Corporate Governance (ESG) report. This marks the fifth year InnoCare has issued its ESG report, and the first year InnoCare has set up specific environmental management targets.
In the...

$INNOCARE (09969.HK)$ $InnoCare Pharma (688428.SH)$ The American Journal of Hematology recently published the results of a phase II study of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in patients with patients with persistent or chronic primary immune thrombocytopenia (ITP), which evaluated the efficacy and safety of orelabrutinib in adult patients with persistent or chronic ITP. The jour...

$WuXi AppTec (603259.SH)$ 🗑️💩🗑️

InnoCare Pharma ( $INNOCARE (09969.HK)$ $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare’s novel SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor, ICP-189, with ArriVent’s furmonertin...